NuGeneris Specialty Pharmaceuticals

NuGeneris Specialty Pharmaceuticals was a Canadian radiopharmaceutical manufacturing company based in Hamilton, Ontario. It operated as a subsidiary of the Centre for Probe Development and Commercialization and was described as a global commercial-stage radiopharmaceutical manufacturing service provider. Publicly available materials indicate it supported commercial-scale production of medical isotopes, including non-carrier-added lutetium-177, and provided manufacturing services for radiopharmaceutical customers in North America. The federal corporation was incorporated in 2016 and later dissolved in November 2022. Based on the available record, NuGeneris appears to have functioned primarily as a specialized radiopharmaceutical manufacturing and supply company rather than a developer of a broad proprietary clinical pipeline.